BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Finite-Lived Intangible Assets, Net by Quarter
Finite-Lived Intangible Assets, Net ($M) ($M)
BeOne Medicines Finite-Lived Intangible Assets, Net: $61M in Q2 2026, down 6.0% from a year earlier.
Latest, Q2 2026
61
Period ended Jun 30, 2026
Change on a year earlier
-6.0%
64.9 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Intangible Assets Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-Lived Intangible Assets, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 61 | -6.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 61.7 | +23.2% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 62.7 | +22.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 63.6 | +18.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 64.9 | +20.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 50.1 | -9.2% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 51.1 | -10.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 53.9 | +0.4% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 53.7 | +14.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 55.2 | +39.0% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 57.1 | +40.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 53.7 | +31.3% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 46.9 | +8.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 39.7 | -13.3% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 40.6 | -13.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 40.9 | +190.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 43.3 | +260.8% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 45.8 | +854.2% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 46.7 | +834.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 14.1 | +171.2% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 12 | +122.2% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 4.80 | -14.3% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 5 | -13.8% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 5.20 | -16.1% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 5.40 | -16.9% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 5.60 | -17.6% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 5.80 | -19.4% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 6.20 | -15.1% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 6.50 | -5.8% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 6.80 | -4.2% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 7.20 | 0.0% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 7.30 | -1.4% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 6.90 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 7.10 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 7.20 | – | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Sep 30, 2017 | 7.40 | – | 10-Q FY2017 (XBRL) ↗ |
Breakdown
What makes up finite-Lived Intangible Assets, Net
- Finite-Lived Intangible Assets, Gross ($M)88.5 · Q2 2026
- Accumulated Amortization — Finite-Lived Intangible Assets ($M)27.5 · Q2 2026
- Net Intangibles — Developed Technology Rights ($M)60.5 · Q2 2026
- Net Intangibles — Licensing Agreements ($M)0.50 · Q2 2026
- Amortization of Intangible Assets — Total ($M)1.60 · Q2 2026
- Estimated Intangible Amortization — Next 12 Months / Year 1 ($M)6.50 · Q2 2026
- Estimated Intangible Amortization — Year 2 ($M)6.50 · Q2 2026
- Estimated Intangible Amortization — Year 3 ($M)6.50 · Q2 2026
- Estimated Intangible Amortization — Year 4 ($M)6.50 · Q2 2026
- Estimated Intangible Amortization — Year 5 ($M)–
- Estimated Intangible Amortization — Thereafter ($M)–
Cite this data
StockData. (2026). BeOne Medicines Finite-Lived Intangible Assets, Net ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/intang-net-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.